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Abstract
Background: Genetic variants identified through genome-wide association studies (GWAS) are predominantly non-
coding and typically attributed to altered regulatory elements such as enhancers and promoters. However, the
contribution of non-coding RNAs to complex traits is not clear.
Results: Using targeted RNA sequencing, we systematically annotated multi-exonic non-coding RNA (mencRNA)
genes transcribed from 1.5-Mb intervals surrounding 139 breast cancer GWAS signals and assessed their
contribution to breast cancer risk. We identify more than 4000 mencRNA genes and show their expression
distinguishes normal breast tissue from tumors and different breast cancer subtypes. Importantly, breast cancer risk
variants, identified through genetic fine-mapping, are significantly enriched in mencRNA exons, but not the
promoters or introns. eQTL analyses identify mencRNAs whose expression is associated with risk variants.
Furthermore, chromatin interaction data identify hundreds of mencRNA promoters that loop to regions that
contain breast cancer risk variants.
Conclusions: We have compiled the largest catalog of breast cancer-associated mencRNAs to date and provide
evidence that modulation of mencRNAs by GWAS variants may provide an alternative mechanism underlying
complex traits.
Introduction
The human genome is extensively transcribed. The
majority of transcripts are long non-coding RNAs
(lncRNAs), defined as > 200 base pairs in length and
transcribed antisense, intronic or intergenic to protein-
coding genes. RNA sequencing studies conducted on
different tissues and cell types are continually identifying
new lncRNAs, which indicates that comprehensive
annotation of lncRNA genes is far from complete [1–6].
Recent studies, using targeted RNA sequencing (also
called RNA CaptureSeq), have revealed tremendous
complexity of human transcriptomes—predominantly
driven by pervasive transcription, complex alternative
splicing, cell type, and context-specific gene expression
[7, 8]. However, to date, only a small number of
lncRNAs have an assigned function and the exact pro-
portion of non-coding transcripts that are functional is a
subject of continued debate.
Genome-wide association studies (GWAS) in com-
bination with fine-mapping have identified 196 inde-
pendent signals associated with breast cancer risk
(conditional p values < 1 × 10−6) [9]. Sixty-six signals
confer a greater risk of estrogen receptor (ER)-positive
tumors, 29 confer a greater risk of developing ER-
negative tumors, and the remaining signals showed no
statistically significant difference in their effects on ER
subtypes [9]. Due to complex linkage disequilibrium
(LD), genetic variants within a signal are frequently co-
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inherited making it difficult to pinpoint the variant
driving the association. A recent study has defined the
credible causal variants (CCVs) within each signal as
those with p values within two orders of magnitude
from the lead variant (7394 CCVs/196) [9]. At 28 sig-
nals, a single CCV was identified, and at 96 signals, the
number of CCVs was ≤ 10. Similar to other trait-
associated variants identified by GWAS, the majority
of CCVs are located in non-coding genomic regions
[1].
We have recently shown that CCVs are enriched in
genomic features associated with regulatory activity in
a range of breast-derived cell lines including sites of
open chromatin, chromatin marks associated with pro-
moter and enhancer activity (H3K4Me3, H3K4Me1,
and H3K27Ac), and transcription factor binding sites
[9, 10]. Capture Hi-C analyses have identified anno-
tated gene promoters that frequently interact with
these CCV-containing elements providing a list of can-
didate risk genes for these signals [10]. However, at 20
signals, we found no evidence of CCVs falling in re-
gions marked by regulatory activity suggesting that
some signals alter risk through alternative mechanisms
[10]. Using RNA CaptureSeq, we annotated multi-
exonic non-coding RNAs (mencRNAs) transcribed
from genome intervals surrounding breast cancer risk
signals in a range of mammary-derived tissue and cell
lines. We provide evidence that non-coding RNAs rep-
resent an alternative mechanism by which CCVs alter
breast cancer risk. This likely extends beyond breast
cancer and may represent a common mechanism by
which GWAS variants act in other complex traits and
diseases.
Results
RNA CaptureSeq array design and capture
To identify non-coding RNAs (ncRNAs) transcribed
from breast cancer risk signals, we performed RNA
CaptureSeq on 21 breast-derived samples including pri-
mary mammary epithelial cells from reduction mammo-
plasties, breast tumor samples, and normal mammary
epithelial and breast cancer cell lines (Fig. 1a, b;
Additional file 2: Tables S1 and S2). Oligonucleotide
probes were designed to capture RNA transcripts pro-
duced from intronic and intergenic regions within 1.5-
Mb intervals surrounding known breast cancer GWAS
signals at the time of capture design (139/196 signals;
Fig. 1a; Additional file 2: Table S3). Additional control
sequences were added to the capture design to assess
performance, including sequences corresponding to ERCC
(External RNA Controls Consortium) spike-in transcripts
and control housekeeping genes (Additional file 2: Table S4).
In total, 138 Mb (4.3%) of the human genome was
covered. RNA sequencing libraries were generated,
hybridized against the capture probes, and sequenced.
In addition, pre-captured RNA-seq libraries from four
cell lines were sequenced to compare enrichment of
the captured transcripts before and after hybridization.
Based on the ERCC controls, the lower limit of detec-
tion (LLD), defined as the lowest molar amount of
ERCC transcript detected in each library, was ~ 300
times lower across the four captured libraries compared to
non-captured controls (Additional file 1: Figure S1).
Moreover, the captured libraries showed a high enrich-
ment of all control housekeeping genes included in the
capture and no enrichment of off-target controls when
compared to the non-captured libraries (p = 3.5 × 10−10;
Additional file 1: Figure S2a).
Annotation of mencRNAs at regions flanking 139 breast
cancer risk signals
To discover novel ncRNA genes, sequencing reads from
the 21 captured libraries were de novo assembled, mapped
back to the genome, and quantified (Additional file 2:
Table S2). ncRNA genes overlapping annotated coding
sequences were excluded. Lowly expressed (maximum
FPKM across the samples < 0.5) and single-exon genes
were also removed to avoid artifacts derived from gen-
omic DNA and transcriptional noise [7]. We identified
4020 mencRNA genes (FPKM ≥ 0.5), 2766 of which are
novel (defined as not overlapping with lncRNAs re-
ported by GENCODE v.19 [11], FANTOM-CAT [12],
or NONCODE [13]) (Additional file 2: Tables S5 and
S6). mencRNA transcript lengths ranged from 143 to
35,678 bp with a median length of 1550 bp (Fig. 1c).
The Coding Potential Calculator [14] predicted a high
proportion of the transcripts (94.03%) as “non-coding,”
significantly more than GENCODE lncRNAs (chi-
square p = 2.5 × 10−5; Additional file 2: Table S7). In
silico assessment of the mencRNA transcripts showed
the vast majority of splice junctions contained canonical
dinucleotides (99.0%), were identified by uniquely map-
ping reads (81.3%), and were not overlapping with repeat
sequences (96.1%) (Additional file 1: Figure S2b-d).
Furthermore, similar to other studies [2], we show a high
prevalence of two-exon lncRNA transcripts (Additional file 1:
Figure S2e). On average, the mencRNA transcripts showed
~ 5.5 times lower expression compared to GENCODE
lncRNAs detected by our RNA CaptureSeq (n = 328;
Additional file 1: Figure S2f). This is likely due to the
targeted RNA sequencing approach, which enabled the
identification of transcripts with lower expression
levels. Hierarchical clustering of the mencRNA expres-
sion profiles clustered the samples according to their
estrogen receptor status, whether they were derived
from normal or tumor samples or from primary tissue
or cell lines (Fig. 1d). Thirty mencRNAs containing
CCVs were prioritized for RT-PCR validation which
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was then performed on the captured transcripts,
binned into three groups of ten based on their level of
expression. Ninety percent of transcripts with a FPKM
≥ 2 were validated by RT-PCR (9/10) compared to 80%
of transcripts with 0.5 ≤ FPKM < 2 and 30% of tran-
scripts with FPKM < 0.5 (Additional file 1: Figure S3a).
As exposure to estrogen is known to promote the de-
velopment of breast cancer, we treated MCF7 breast
cancer cells with 17beta-estradiol to determine if
expression of any mencRNAs was estrogen-regulated
(Additional file 1: Figure S3b). Nearly one third of the
mencRNAs (n = 1189) were differentially expressed
between MCF7 estrogen-treated and vehicle-treated con-
trol libraries (FDR < 0.01; Additional file 1: Figure S3c;
Additional file 2: Table S8). We then quantified the
expression of our captured transcripts in 111 normal
breast samples and 1092 breast tumors using standard
RNA-seq datasets from TCGA [15]. Approximately 75%
of the mencRNAs were present at an expression level of
FPKM ≥ 1 even though no capture step had been per-
formed prior to sequencing (Additional file 2: Table S9).
Consistent with other non-coding RNAs, our mencR-
NAs had on average 140-fold lower expression
compared with GENCODE protein-coding genes
(Fig. 1e). Principal component analyses (PCA) based
on mencRNA expression distinguished normal breast
tissue from matched breast tumor, PAM50 breast can-
cer subtypes, and ER-positive versus ER-negative
breast tumors (Fig. 1f, g; Additional file 1: Figure S3d).
We also analyzed the expression of the mencRNAs in
six additional tumor types and show that the mencR-
NAs exhibit high tissue specificity compared to
protein-coding genes (Fig. 1h). PCA analyses based on
mencRNA expression also tightly clustered tumors
based on tissue type (Additional file 1: Figure S3e).
Enrichment of CCVs for breast cancer risk in mencRNA
exons
Several studies have shown that most genetic variants
identified through GWAS are non-coding and enriched
in cell type-specific enhancers relevant to the GWAS
trait [9, 16]. However, the contribution of non-coding
RNAs to complex traits is not clear. We assessed the
mechanisms underlying CCVs and mencRNAs and
showed enrichment of CCVs in the exons, but not the
promoters or introns of the mencRNAs (Fig. 2a). Con-
versely, CCVs were depleted in the exons of protein-
coding genes and enriched in the introns. In total, 119
mencRNA genes at 69/139 signals contained a CCV
(417 in total; Additional file 2: Tables S10 and S11)
within a mencRNA exon. One example is the 2q14.2 risk
region, where CCVs in 3 of the 4 independent risk sig-
nals fell within mencRNA exons (Fig. 2b, c). Of note,
CCVs within signals 2 and 3 fell in different exons of the
same mencRNA, XLOC-130206 (Fig. 2c).
Given the enrichment of CCVs in mencRNA exons,
we hypothesized that CCVs could affect mencRNAs by
modulating RNA stability. We therefore performed an
expression quantitative trait loci (eQTL) study using the
breast tumor TCGA datasets to identify genetic varia-
tions associated with mencRNA expression. We identi-
fied 800 mencRNAs which were eQTLs (FDR < 0.05),
nine of these eQTLs overlapped with breast cancer signals,
based on the p value for the top eQTL SNP being within
two orders of magnitude of the eQTL p value for a CCV.
We further examined the colocalization of the eQTL and
breast cancer signals and show that seven of the nine
eQTLs colocalize (Additional file 1: Figure S4;
Additional file 2: Tables S12 and S13). Of these, three
signals have at least one eQTL variant (eVariant) within a
mencRNA exon (Additional file 2: Tables S12 and S13).
(See figure on previous page.)
Fig. 1 Identification of mencRNAs from breast cancer GWAS risk regions. a Schematic of the RNA CaptureSeq experimental design.
Oligonucleotide probes were tiled across intronic and intergenic regions within 1.5-Mb intervals surrounding breast cancer risk regions (capturing
~ 138 Mb or 4.3% of the human genome). The probes were hybridized to cDNAs from breast-derived cell lines and tissues resulting in capture
and enrichment of low abundance transcripts in target regions that were then sequenced. The sequencing reads were de novo assembled,
mapped, and quantified. b The number of transcripts captured from each RNA CaptureSeq library. The libraries included nine breast-derived cell
lines, four breast tumor (BT) samples, and four breast normal (NB) samples. Four non-captured libraries were also sequenced. c Distribution of
mencRNA transcript length. Pooled captured transcripts from all libraries were binned based on their transcript lengths. d Hierarchical clustering
of RNA CaptureSeq libraries based on mencRNA expression profiles. ER-positive breast cancer cell lines and tumors are shown in red, ER-negative
breast cancer cell lines are shown in blue, and normal breast cell lines and tissues are shown in black. NC non-captured, NB normal breast, BT
breast tumor. The y-axis of the dendrogram represents a distance measure between the clusters. e Expression distribution of captured mencRNA
transcripts versus protein-coding transcripts. Multi-exonic captured transcripts with max. FPKM ≥ 0.5 were mapped in TCGA RNA-Seq data and
their average expression across the TCGA tumors were compared to GENCODE protein-coding genes. The y-axis represents the frequency of
transcripts with a given expression value represented as log2 (average FPKM) on the x-axis. f Principal component analysis (PCA) of captured
transcripts in TCGA normal breast and matched tumor samples. Scaled, centred, and normalized expression of the captured transcripts were
analyzed for the first (x-axis; PC1) and second (y-axis; PC2) principal components. Each dot represents expression profile of an individual sample.
g PCA of the captured transcripts in different PAM50 breast cancer subtypes. h Comparison of tissue-specific expression of captured mencRNA
versus protein-coding transcripts. Multi-exonic captured transcripts with max. FPKM ≥ 0.5 and GENCODE protein-coding genes were mapped in
TCGA RNA-seq data for primary tumors from seven different cancer types. For each gene, tissue specificity index (Tau) was measured with 0 and
1, indicating broad and tissue-specific expression, respectively. The y-axis represents the frequency of transcripts with a given Tau value
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For example, the eVariants at 2q31.1 (FDR = 0.002) fell
within an exon of a mencRNA called XLOC-142280 with
the risk alleles associated with reduced expression
(Fig. 3a–c; Additional file 1: Figure S5a; Additional file 2:
Tables S12 and S13). Notably, eQTL studies in multiple
normal and breast tumor cohorts did not find an associ-
ation between CCVs at this signal and any annotated
protein-coding genes (at p < 5 × 10−4), suggesting that
XLOC-142280 is a likely target gene [17]. Using TCGA
RNA-seq data, we show that XLOC-142280 is predomin-
antly expressed in ER-positive breast cancers (Fig. 3d).
Given that CCVs at this region are exclusively linked with
ER-positive breast cancer, this association could be ex-
plained by the restricted breast cancer subtype expression
of XLOC-142280 [9].
Evidence for distal CCVs modulating mencRNAs
For 4/7 of the eQTLs that colocalized with breast can-
cer risk signals, there were no eVariants in mencRNA
exons. Therefore, we speculated that CCVs may also
act distally through regulatory elements that interact
with mencRNA promoters. Using Capture Hi-C data
from breast cells [10], we identified 770 mencRNA
promoters (defined as ± 500 bp from the transcription
start site) that looped to a region containing a CCV
(Additional file 2: Tables S11 and S14). For example, at
16q12.2, CCV rs11642015 is an eVariant (p < 5 × 10−4)
for the mencRNA XLOC-093918, with the risk haplo-
type associated with increased XLOC-093918 levels
(Fig. 4a; Additional file 1: Figure S5b; Additional file 2:
Tables S12 and S13). CCV rs11642015 falls within a
region of open chromatin marked by H3K27ac and
H3K4me1, consistent with a putative enhancer element
and contacts XLOC-093918 in B80T5 normal breast
cells and ER-positive and ER-negative breast cancer
cell lines (Fig. 4b, c; Additional file 1: Figure S5c). The
CCV also contacts the IRX5/CRNDE bidirectional pro-
moter; however, no eQTL for IRX5 or CRNDE or any
other gene was detected in either normal or tumor tis-
sues (at p < 5 × 10−4) [17].
In another example, we show that promoters of three
mencRNAs (XLOC-214919, XLOC-222497, and XLOC-
222554) located at the 6q25/ESR1 risk region participate
in chromatin looping with regions containing CCVs
(Fig. 5a). Interestingly, we also observed looping between
the ESR1 promoter and both XLOC-222497 and XLOC-
222554 (Fig. 5a) and the expression of both mencRNAs
was highly correlated with ESR1 (Fig. 5b), suggesting
Fig. 2 Enrichment of CCVs in mencRNA exons. a The overlap of CCVs with non-coding (ncRNA) and protein-coding transcript features. The
number of CCVs directly overlapping a feature is shown in blue, and gray bars show the expected values based on overlap with 105 randomly
generated interval sets. Error bars show the 95% confidence intervals of the mean. The significance of the enrichment is expressed as p values,
calculated by dividing the number of random samples showing equal or greater overlap than the observed by the total number of permutations
(*p < 0.05). b WashU genome browser showing annotated GENCODE genes (blue), and mencRNAs (black) within the 2q14.2 risk region. The
XLOC-130152 and XLOC-130206 mencRNAs are highlighted in red. Risk signals 1–4 are numbered and the CCVs within each signal shown as
colored vertical lines. The dashed gray outlines highlight the CCVs and relevant mencRNAs. c Zoomed in view of signals 1–3 CCVs, XLOC-130152
and XLOC-130206
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that these genes are co-regulated or are themselves regu-
latory mencRNAs that mediate cis-regulation of ESR1.
Given the high correlation between the mencRNA-
mRNA pairs at 6q25, which are connected by chromatin
loops, we investigated whether mencRNA-mRNA pairs
connected by loops across our captured regions were
more highly correlated than mencRNA-mRNA pairs not
connected. Although the effect size is marginal, we
found that the expression of mencRNA-mRNA pairs
that are physically connected through chromatin looping
are significantly more correlated than a random set of
mencRNA-mRNA pairs (Fig. 5c).
Evidence for mencRNAs being the target gene of more
than one signal
Recent fine-scale mapping of breast cancer GWAS risk
regions have reported multiple independent risk sig-
nals, some of which target the same protein-coding
gene [9, 10]. We therefore sought to identify mencR-
NAs that are targeted by more than one risk signal.
We identified 222 mencRNA genes in which two or
more independent CCVs fell either (i) within the exon
of the mencRNA, (ii) within the promoter region of
the mencRNA, or (iii) in a region that interacts through
long-range chromatin interactions with the promoter of
the mencRNA (Additional file 2: Table S14). For example,
at 18q11.2, we identified an eQTL variant for XLOC-
112072 (FDR = 1.95 × 10−10) that overlaps signal 3 CCVs
(Fig. 6a–c; Additional file 1: Figure S5d), two of which fall
in the mencRNA exon. In addition, signals 1 and 2 loop to
the promoter of XLOC-112072 in T47D breast cancer
cells (Fig. 6b). Interestingly, only signal 1 interacts with
the XLOC-112072 promoter in B80T5 normal breast cells,
suggesting some level of cell-type specificity (Fig. 6b). Not-
ably, no other protein-coding eQTLs were identified for
signals 1, 2, or 3 (p < 5 × 10−4), supporting a role for this
mencRNA as one of the likely target genes at this breast
cancer risk signal.
Discussion
To date, the major focus of GWAS follow-up studies has
been the impact of regulatory variants on the expression
Fig. 3 mencRNAs with eVariants in an exon. a Regional XLOC-142280 eQTL association plot. Red dots indicate CCVs within the region. b WashU
genome browser showing annotated GENCODE genes (blue) and mencRNAs (black) within the 2q31.1 risk region. The XLOC-142280 mencRNA is
highlighted in red. CCVs are shown as red colored vertical lines. The dashed gray outline highlights the XLOC-142280 mencRNA. c Zoomed in
view of CCVs and XLOC-142280. d Box plot showing the expression of XLOC-142280 in ER-negative versus ER-positive breast tumor samples from
TCGA RNA-seq data
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of protein-coding genes. In many cases, genetic variants
with stronger genetic associations with the trait of inter-
est are dismissed as causal because they do not fall in
regions marked for promoter or enhancer activity.
Using a combination of targeted RNA sequencing and
de novo transcript assembly, we annotated > 4000
mencRNA genes expressed from genomic intervals
surrounding 139 breast cancer GWAS signals. We
identify 844 mencRNAs as candidate breast cancer risk
genes based on CCVs that fall in either (1) mencRNA
exons, (2) mencRNA promoters, or (3) regions that
interact with the mencRNA promoters through long-
range chromatin interactions. We summarize the evi-
dence for mencRNA involvement at breast cancer risk
signals (Additional file 2: Table S11), which will facili-
tate future lab-based functional studies. Collectively,
these results suggest that modulation of mencRNAs
may represent an alternative mechanism by which
CCVs contribute to risk.
Our eQTL analyses identified nine mencRNA eQTLs
which colocalize with breast cancer risk signals. Of
these, five were the only detectable eQTL for the signal
Fig. 4 mencRNAs linked to distal CCVs at 16q12. a Regional XLOC-93918 eQTL association plot. Red dots indicate CCVs within the region. b
WashU genome browser showing annotated GENCODE genes (blue) and mencRNAs (black) within the 16q12.2 risk region. The XLOC-93918
mencRNA is highlighted in red. CCVs are shown as red colored vertical lines. The ATAC-seq data is shown as a blue histogram, histone
modification ChIP-seq data is shown as black histograms, and CHi-C chromatin interactions are shown as arcs from the B80T5 breast cell line. Red
arcs depict chromatin looping between CCVs and the XLOC-93918 promoter region. c Zoomed in view of CHi-C interaction and XLOC-93918
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providing evidence that these mencRNAs are at least
one of the likely candidate target genes at the respective
signal. Three of the seven mencRNAs had an eVariant
within the mencRNA exon. However, there were other
genetic variants in LD which were more distal (CCVs in
the same signal), making it difficult to determine if the
exonic eVariant is affecting the mencRNA stability and
driving the association. For example, the CCVs within
the same signal that lie outside of mencRNA exons
could potentially effect mencRNA expression through al-
tered cis-regulatory elements (e.g., mencRNA promoters
or enhancers). Consistent with this, for 4/7 mencRNA
eQTLs that overlap breast cancer risk signals, the eVar-
iants fall outside the mencRNA exons suggesting that, in
these cases, altered distal regulation is the more likely
mechanism. We have already demonstrated this regula-
tory mechanism at the 11q13 breast cancer risk region
[18]. CCVs at 11q13 fall within an estrogen-regulated
enhancer of two lncRNAs called CUPID1 and CUPID2.
In heterozygous breast cancer cell lines, we showed
allele-specific chromatin looping between the enhancer
and the CUPID1/2 bidirectional promoter suggesting
CCVs reduce their expression by inhibiting chromatin
looping [18]. CUPID1/2 play a role in modulating
Fig. 5 mencRNAs linked to distal CCVs at 6q25. a WashU genome browser showing annotated GENCODE genes (blue) and mencRNAs (black)
within the 6q25 risk region. mencRNAs whose promoters participate in chromatin interactions with CCVs are highlighted in blue, green, and red.
CCVs are shown as colored vertical lines. The ATAC-seq data is shown as a blue histogram, histone modification ChIP-seq data is shown as black
histograms, and CHi-C chromatin interactions are shown as arcs from the MCF7 breast cancer cell line. Colored arcs depict chromatin looping
between CCVs and color-matched mencRNA promoter regions. b Correlation between expression of the three captured transcripts and ESR1 in
the TCGA cohort. Each dot in the scatterplots represents a breast cancer individual with gene expression values being plotted as log2 (FPKM) on
the x- and y-axes. c Boxplot showing absolute correlation coefficient values compared between looped and non-looped pairs of mencRNAs and
nearby protein-coding genes (within 1 Mb up- and downstream)
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pathway choice for the repair of double-stranded DNA
breaks by promoting homologous recombination-based
repair [18], providing a plausible mechanism by which
CCVs alter breast cancer risk. In another example, pros-
tate cancer risk variants at 8q24 increase the activity of
an enhancer for the PCAT1 lncRNA. PCAT1 interacts
Fig. 6 mencRNAs targeted by multiple risk signals. a Regional XLOC-112072 eQTL association plot. Red dots indicate signal 3 CCVs. b WashU
genome browser showing annotated GENCODE genes (blue) and mencRNAs (black) within the 18q11 risk region. The XLOC-112072 mencRNA is
highlighted in red. Risk signals 1–3 are numbered and the CCVs within each signal shown as colored vertical lines. The ATAC-seq data are shown
as blue histograms, histone modification ChIP-seq data is shown as black histograms, and CHi-C chromatin interactions are shown as arcs from
T47D and B80T5 breast cell lines. Red arcs depict chromatin looping between CCVs and the XLOC-112072 promoter region. c Zoomed in view of
CCVs, CHi-C interaction, and XLOC-9112072
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with the androgen receptor and lysine-specific demethy-
lase to promote prostate cell growth providing a mech-
anism by which genetic variants increase risk of prostate
cancer [19].
We show that CCVs are enriched in the exons but not
the introns or promoters of mencRNAs, suggesting that
genetic variants may alter mencRNA structure and/or
function. lncRNAs can act as protein scaffolds; therefore
it is possible that a genetic variant could alter the bind-
ing of proteins to mencRNAs. For example, LINP1 pro-
motes the repair of DNA breaks by acting as a scaffold
for proteins involved in non-homologous end joining
(NHEJ) [20]. The 2q12.1 region associated with celiac
disease provides an example of genetic variants affecting
lncRNA function at a GWAS locus. This study showed
that risk-associated variants repress the expression of in-
flammatory genes by altering the secondary structure of
a lncRNA called Lnc13 and ultimately the binding of
hnRNPD to Lnc13 [21]. At some breast cancer risk sig-
nals where no eQTL association was found, we speculate
that CCVs may be functional without affecting gene ex-
pression. This is certainly the case for somatic mutations
in two lncRNAs, MALAT1 and NEAT1, where levels of
these lncRNAs are not significantly altered in mutated
vs non-mutated samples [22].
CCVs are also enriched in genomic features associated
with cis-regulatory DNA elements including sites of
open chromatin, chromatin marks associated with pro-
moter and enhancer activity, and transcription factor
binding sites [9, 10]. Given that lncRNAs often arise
from enhancer elements [23–25], it is possible that some
CCV-containing enhancers fall within mencRNAs. Not-
ably, we did not observe enrichment of CCVs in the
introns or promoter regions of mencRNAs, suggesting
that alteration of the lncRNAs transcribed from en-
hancers may have a functional effect on the enhancer
activity. Several lncRNAs are required for promoting
chromatin looping between enhancers and promoters
[26–28]. Therefore, it is possible that genetic variants
within the lncRNA could affect this process. Further
work will be required to determine whether the CCVs
that overlap mencRNAs and enhancers in this study act
through the DNA element, for example, by altering tran-
scription factor binding, or whether the variant affects
the RNA transcript itself.
Conclusions
In summary, we have compiled the largest catalog of
breast cancer-associated mencRNAs to date and provide
evidence that modulation of mencRNAs by GWAS vari-
ants may provide an alternative mechanism underlying
complex traits. These findings have broad implications
for interpreting findings from GWAS and suggest that
comprehensive annotation of ncRNAs expressed in
relevant cell types around GWAS signals will be import-
ant for functional follow-up studies. We do not yet know
what proportion of mencRNAs identified in this study
are functional. However, even if a small percentage have
evolved functions, this resource may contain hundreds
of new genes that hold the key to understanding breast
cancer etiology. lncRNAs display remarkable cell and
tissue-specific expression making them excellent candi-
dates for therapeutic targets. Understanding the function
of these lncRNAs therefore holds great potential for the
development of new breast cancer therapies.
Methods
Availability of data and materials
Processed RNA sequencing and chromatin interaction data
can be visualized at the Washington Epigenome Browser
via https://bit.ly/2E1EpmC. Processed RNA sequencing
data is available from https://osf.io/ew86n/?view_only=8d2
c5c17dff54fb98daa3cfe51d2d473. Raw sequencing data has
been deposited at the European Genome-phenome Archive
(EGA) which is hosted at the EBI and the CRG, under the
accession number EGAS00001003353. The custom scripts
used in the study are available from https://github.com/
MahdiMoradiMarjaneh/ncRNAs_BRCA_GenomeBiol2019.
All datasets and software used are listed in
Additional file 2: Table S16 [10, 14, 29–36].
Breast cell lines
ER-positive breast cancer cell lines MCF7, T47D, and
BT474 were grown in RPMI medium with 10% (vol/vol)
fetal calf serum (FCS), 1 mM sodium pyruvate, 10 μg/mL
insulin, and 1% (vol/vol) antibiotics. ER-negative breast
cancer cell lines MDA-MB-231, MDA-MB-468, and
Hs578T were grown in RPMI medium with 10% (vol/
vol) FCS and 1% (vol/vol) antibiotics. The normal breast
epithelial cell line MCF10A was grown in DMEM/F12
medium with 5% (vol/vol) horse serum, 10 μg/ml insulin,
0.5 μg/ml hydrocortisone, 20 ng/ml epidermal growth
factor, 100 ng/ml cholera toxin, and 1% (vol/vol) antibi-
otics. The normal breast epithelial cell line B80-hTERT1
(provided by Roger Reddel, CMRI, Australia) was grown
in a 1:1 mixture of MCDB 170 and RPMI 1640 media
with 10% (vol/vol) FCS and 1% (vol/vol) antibiotics. Pri-
mary human mammary epithelial cells (HMECs) were
grown in basal medium (MEBM, Lonza) supplemented
with SingleQuots (MEGM BulletKit, Lonza). Cell lines
were maintained under standard conditions (37 °C, 5%
CO2), tested for Mycoplasma, and profiled for short
tandem repeats.
Human samples
Normal breast samples were derived from reduction
mammoplasty from four donors, and organoids were ob-
tained according to Johnson et al. [37].
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RNA CaptureSeq array design
Oligonucleotide probes were designed to capture non-
coding sequences within 1.5-Mb intervals surrounding
breast cancer GWAS signals using Roche NimbleGen’s
capture design algorithm. To evaluate performance of
the RNA CaptureSeq, control sequences were added to
the design including 92 ERCC spike-in transcripts and
9 housekeeping genes covering a range of expression
levels across breast tissues (ABCB1, GATA1, GUSB,
HMBS, HPRT1, NLK, RUNX2, TBP, and TFRC;
Additional file 2: Table S4). In total, 85.8% of the tar-
get bases were captured providing a total capture size
of 137.7 Mb (4.3% of the human genome). The vast
majority (~ 92%) of capture probes were unique
(matched to only one genomic sequence). To increase
the coverage of the remaining targets, a small propor-
tion had multi-sequence homology.
RNA CaptureSeq library preparation and capture
sequencing
RNA was extracted from the primary mammary epithe-
lial cells and normal mammary epithelial and breast can-
cer cell lines using the RNeasy Plus Mini Kit (Qiagen).
Five micrograms of total RNA was rRNA depleted using
the Ribo-Zero Gold rRNA removal kit according to the
manufacturers’ instructions (Illumina). RNA was ex-
tracted from the breast tumor samples using TRIzol
(Thermo Fisher Scientific), then DNase-treated with
Turbo DNase (Life Technologies). ERCC RNA spike-in
control mix 1 or 2 (Life Technologies) were added to
ribodepleted RNA (final dilution of 1/50) or to 200 ng of
total RNA (from breast tumors; final dilution of 1/1250).
RNA-seq libraries were generated using the KAPA
stranded RNA-seq Library Preparation Kit (Roche) and
12 cycles of pre-capture LM-PCR. Multiplex library
pools were created by mixing equal amounts of four
pre-capture libraries and capture hybridization per-
formed on 1 μg of the pooled library. Capture hybrid-
izations were performed using the SeqCap RNA
Enrichment System (NimbleGen) according to the
manufacturer’s instructions. Post-capture LM-PCR was
performed for 14 cycles. One library pool (representing
four original libraries) was sequenced per lane on the
Illumina HiSeq2500 platform (Kinghorn Centre for
Clinical Genomics, Sydney, Australia).
Assessment of RNA CaptureSeq performance
To evaluate fold enrichment, sensitivity, and specificity
of the RNA CaptureSeq, we added control sequences
to the capture design including ERCC spike-in tran-
scripts and housekeeping genes. Before hybridization
of the libraries to the probes, we made technical repli-
cates from four pre-capture libraries (B80-hTERT1,
Hs578T, MCF7, and MDA-MB-231) and sequenced.
Sequencing data from these non-captured and the cor-
responding captured libraries were used to evaluate
the RNA CaptureSeq performance. Adapter trimming
and quality control of the sequencing reads were per-
formed with Trim Galore version 0.3.7. The reads were
then mapped against hg19 reference genome appended
with 92 ERCC spike-in transcripts using STAR version
2.4.2a. RSEM version 1.2.25 was used for transcript
quantification. Expression data for the ERCC spike-in
transcripts were used to assess sensitivity and fold en-
richment of the RNA CaptureSeq. A dose-response
plot for each library was generated by plotting normal-
ized expression (log2 (FPKM)) of the ERCC transcripts
against their known molar concentration added by a
linear regression line of best-fit. To assess the sensitiv-
ity of the platform, we obtained a lower limit of detec-
tion (LLD) from each plot (defined as the lowest
concentration of the ERCC transcripts present in each
library that yields a detectable expression with the de-
tection threshold FPKM of 0.5) and compared between
captured and non-captured libraries. Upper limits of
detection were also determined to assess probe satur-
ation. Fold enrichment of the platform was calculated
using linear regression equations of the captured and
non-captured libraries. We evaluated off-target capture
as a measure of specificity of the RNA CaptureSeq.
Seven housekeeping genes included in the design and
expressed in the samples (GUSB, HMBS, HPRT1, NLK,
RUNX2, TBP, TFRC) were tagged as “targeted” and, for
each, the nearest protein-coding gene not included in
the design (VKORC1L1, H2AFX, PHF6, TMEM97,
SUPT3H, PSMB1, and ZDHHC19) was selected and
tagged as “non-targeted.” For each gene, expression
fold change between the captured and non-captured li-
braries was measured and log-transformed values were
compared between the targeted and non-targeted
genes using a paired Student’s t test.
De novo assembly and transcript characterization
As described previously [7], for each library, the se-
quencing reads were trimmed with Trim Galore ver-
sion 0.3.7, assembled with Trinity version 2.2.0 [29],
and mapped back to the hg19 reference genome with
GMAP version 2015-11-20 [30]. The transcripts from
all libraries were then merged together using the
Cuffmerge function of Cufflinks version 2.2.1 [31]. The
sequencing reads were then mapped against the
merged assembly using STAR version 2.4.2a [32] and
quantified using RSEM version 1.2.25 [33]. Single-exon
genes, those not overlapping breast cancer GWAS re-
gions, and those overlapping protein-coding sequences
were removed. Moreover, we excluded lowly expressed
genes (maximum FPKM across all libraries < 0.5) and
isoforms with very low expression (maximum FPKM
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across all libraries < 0.01). The identified mencRNAs were
assessed for coding potential by Coding Potential Calcula-
tor [14]. Splice junctions were annotated and character-
ized using STAR version 2.4.2a. We clustered the samples
based on expression profiles of the mencRNAs using the
“hclust” function from the R “Stats” package. EdgeR Bio-
conductor package [34] was used to identify mencRNAs
differentially expressed between MCF7 estrogen-treated
and vehicle-treated control libraries.
Annotation of the captured transcripts in TCGA cohort
The captured transcripts were filtered for multi-exon
genes and those overlapping with GWAS regions, then
merged with the GENCODE comprehensive gene anno-
tation (release 19) to generate a custom reference anno-
tation file. In the case of overlapping genes, if the RNA
CaptureSeq gene was lowly expressed (maximum FPKM
across all libraries < 0.5), it would be removed and other-
wise the GENCODE gene would be excluded. TCGA
RNA-seq data for breast invasive carcinoma cohort
(1226 samples), cervical squamous cell carcinoma (n =
309), esophageal carcinoma (n = 165), mesothelioma
(n = 86), prostate adenocarcinoma (n = 552), skin cuta-
neous melanoma (n = 463), and uterine corpus endomet-
rial carcinoma (n = 175) cohorts was obtained from
Cancer Genomics Hub. Adaptor trimming of the se-
quencing reads was performed using Cutadapt version
1.11. Using the custom reference annotation file, the
reads were then mapped with STAR version 2.5.2a and
quantified with RSEM version 1.2.30 [32, 33]. Since
TCGA RNA-seq data is not strand-specific, we excluded
the captured transcripts which overlap (≥ 1 bp) with
exons of protein-coding genes on the opposite strand in
order to prevent bias when assessing expression levels.
For differential expression analysis, genes with low ex-
pression (less than five counts per million in less than
five samples) were excluded. The remaining expression
data were imported into edgeR Bioconductor package
[34] and normalized for library size and RNA compos-
ition. Differential expression analysis was then per-
formed using edgeR functions glmFit and glmLRT. We
used the R function prcomp for principal component
analysis (PCA). For co-expression analysis, genes with
low expression (expression counts in less than 20% of
samples) or low variability (median absolute deviation
(MAD) across the samples < 1) were excluded. Pairwise
correlations were then computed using the R cor func-
tion. Tissue specificity index (Tau) [38] was measured
using log2-transformed expression data for primary
tumor samples from the seven TCGA cancer cohorts.
RT-PCR validation of the captured lncRNAs
We used RT-PCR to validate 30 captured lncRNAs,
binned into three groups based on their level of
detection in T47D breast cancer cells. mencRNAs
expressed at FPKM > 2 were classified as high
expressed, 0.5 ≤ FPKM < 2 as moderate expressed, and
FPKM < 0.5 as low expressed. Five micrograms of total
RNA was first reverse transcribed using SuperScript III
(Life Technologies), and PCR was performed using
MyTaq DNA polymerase according to the manufac-
turers’ instructions. Forty cycles were performed in
order to identify low expressed transcripts. Forward
primers and reverse primers were designed to different
mencRNA exons to avoid amplification of genomic
DNA. Primers are listed in Additional file 2: Table S15.
CCV enrichment analyses
We first examined the overlap of CCVs and mencRNAs
genes. Variants were intersected with mencRNA exons,
introns, and promoter sequences (defined as 500 bp up-
stream of the transcription start site). Fold enrichment
was calculated by dividing the proportion of CCVs that
overlapped the annotations by the proportion of cover-
age of that annotation within the captured regions. The
significance of the overlap was calculated by comparing
it to the expected using a hypergeometric test using Bed-
tools fisher. To further analyze CCV overlap, positions
of each annotation were permuted around circularized
capture regions. This approach maintained the relative
sizes and positions of annotations belonging to the same
transcript. Overlap of CCVs was compared to the mean
overlap for 105 random permutations.
mencRNA eQTL analyses
RNA-seq reads from TCGA breast invasive carcinoma
cohort were mapped against mencRNAs and quantified
as described above. For these analyses, we did not filter
the mencRNAs based on RNA CaptureSeq expression.
The expression data for tumors (n = 1112) were then
analyzed for eQTL detection. Patient germline SNP
genotypes (Affymetrix 6.0 arrays) were processed and
imputed to the 1000 Genomes reference panel (October
2014) as previously described [17]. Tumor tissue copy
number was estimated from the Affymetrix 6.0 arrays
and called using the GISTIC2 algorithm [35]. Complete
genotype, RNA-seq, and copy number data were avail-
able for 678 genetically European patients. The FPKM
values were log2 transformed and quantile normalized.
Genetic variants within the captured regions were ex-
tracted from the imputed genotype dataset. The associa-
tions between genetic variants and mencRNA expression
in breast tumor tissue were evaluated using linear re-
gression models by the MatrixEQTL program in R [36].
Tumor tissue was also adjusted for copy number vari-
ation, as previously described [39]. A false discovery rate
of 5% was used to report eQTL results from breast tis-
sue. We considered eQTLs to overlap breast cancer risk
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signals based on the p value for the top eQTL SNP
being within two orders of magnitude of the eQTL
p value for a CCV. Colocalization analysis of eQTL
and breast cancer risk signals was performed as
described by Liu et al. [40].
ATAC-seq and Capture Hi-C
ATAC-seq and Capture Hi-C in breast cells were ob-
tained from Beesley et al. [10].
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